A recent study published in the Journal of Affective Disorders suggests that a single dose of psilocybin may offer hope for U ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

A pioneering study in rural India shows that combining digital healthcare with community campaigns can significantly reduce mental health issues such as depression and anxiety. This approach has not ...

When 73-year-old Ravi went to a primary health centre at Bardez, Goa, to address his exhaustion and sleep problems, little did the healthcare worker realise that these were tell-tale signs of ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

The field of digital therapeutics for mood disorders has witnessed rapid advancements, harnessing cutting-edge technologies to provide personalized, accessible support. These interventions leverage AI ...

Three years after $20 million in federal pandemic aid allowed the University of Iowa in 2021 to open a new “Center for School ...

Approved in March 2019, esketamine is currently indicated for use alongside an oral antidepressant for treatment-resistant ...

At the start of Movember, experts explain the conditions that affect you at every age – and how to protect yourself ...

FOR decades, Sarah Smith suffered with depression. But now, due to a futuristic-looking headset that zapped electronic pulses deep into her brain, her fog has lifted. She tells Sun Health: “It’s ...

Unsupervised use of hallucinogens like LSD is high, posing significant risks. However, LSD is being clinically tested for treating anxiety and so far seems effective.

MindMed is poised for significant developments with MM-120 in upcoming trials. Discover why monitoring MNMD stock is ...